Drugs / GD2 T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01953900 | Apr 2014 → Oct 2019 overdue | neuroblastoma, osteosarcoma | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01953900 ↗ |
| Modality | Cell therapy | “patients are being asked to volunteer to take part in a gene transfer research study using special immune cells.” NCT01953900 ↗ |
| Route | Intravenous | “Patients will receive the GD2-T cells by an intravenous line.” NCT01953900 ↗ |